Kestra Medical Technologies released its fiscal first-quarter 2027 financials after the closing bell, and the stock reacted sharply in after-hours trading, dropping 9.6% as investors grappled with a wider-than-expected loss.
Quarterly results
The company reported an adjusted loss per share of -$0.75 for the quarter ended July 31, 2026, which was materially below the consensus estimate of about -$0.63 and a meaningful deterioration from the -$0.50 adjusted loss recorded in the same quarter a year earlier. While top-line performance showed significant momentum, the bottom line disappointed relative to analyst expectations.
Revenue and margins
Revenue for the quarter came in at $31.0 million, representing 60% year-over-year growth. Gross margin expanded to 56.5% from 45.7% a year earlier, indicating improving unit economics on the company’s sales mix or cost of goods sold dynamics. Management also raised full-year fiscal 2027 revenue guidance to $141 million, up from the prior target of $137 million, which implies roughly 48% growth versus fiscal 2026.
Profitability and expenses
Despite the revenue gains and margin expansion, Kestra’s GAAP net loss widened to $44.1 million from $25.8 million in the prior-year period as operating expenses increased significantly. Adjusted EBITDA deteriorated to a -$24.0 million loss, underscoring continued pressure on the company’s path to profitability even as the top line accelerates.
Market reaction and trading
Shares fell to $21.75 in after-hours trade, below the regular-session low of $22.80. The after-hours decline of 9.6% followed the post-close release of the quarterly results and the larger-than-expected adjusted loss. Broader market indices were essentially flat on the day, with the S&P 500 up 0.1%, the Dow Jones up 0.1% and the Nasdaq rising 0.2%, providing little macro tailwind for a small-cap medtech name facing company-specific headwinds.
Shareholder behavior and market structure
Investor sentiment appeared to be further affected by recent insider activity and short interest. Over the past six months there were 37 open-market insider sales versus a single purchase. Short interest accounted for nearly 11% of the float and has increased sharply over the past year, amplifying downward pressure on the shares.
Competitive pressures
The company also faces a competitive landscape that includes a rival that introduced a next-generation wearable defibrillator in late 2025, a factor noted as continuing to exert pricing and market-share pressure.
Taken together, the sizable earnings miss, expanding GAAP losses, and elevated short interest outweighed positives such as robust revenue growth, margin expansion and a modest guidance raise, leaving the market to push the stock lower in after-hours trading.
Key metrics cited
- Adjusted loss per share: -$0.75 (quarter ended July 31, 2026)
- Consensus adjusted loss estimate: approximately -$0.63
- Prior-year adjusted loss (same quarter): -$0.50
- Revenue: $31.0 million, +60% year-over-year
- Gross margin: 56.5% versus 45.7% a year earlier
- Full-year revenue guidance raised to $141 million from $137 million (implies 48% growth vs fiscal 2026)
- GAAP net loss: $44.1 million versus $25.8 million prior year
- Adjusted EBITDA: -$24.0 million
- Insider open-market sales: 37 versus 1 purchase in past six months
- Short interest: nearly 11% of float
- After-hours share price: $21.75; regular-session low: $22.80